GALAPAGOS NV/S (GLPG) Position Increased by Comerica Bank

Share on StockTwits

Comerica Bank increased its holdings in GALAPAGOS NV/S (NASDAQ:GLPG) by 6.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,120 shares of the biotechnology company’s stock after purchasing an additional 185 shares during the quarter. Comerica Bank’s holdings in GALAPAGOS NV/S were worth $325,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Federated Investors Inc. PA grew its stake in shares of GALAPAGOS NV/S by 17.8% in the third quarter. Federated Investors Inc. PA now owns 1,677,922 shares of the biotechnology company’s stock worth $188,648,000 after purchasing an additional 253,159 shares during the last quarter. BlackRock Inc. boosted its position in GALAPAGOS NV/S by 18.4% during the 3rd quarter. BlackRock Inc. now owns 365,413 shares of the biotechnology company’s stock valued at $41,083,000 after acquiring an additional 56,848 shares in the last quarter. Credit Suisse AG boosted its position in GALAPAGOS NV/S by 52.0% during the 3rd quarter. Credit Suisse AG now owns 190,376 shares of the biotechnology company’s stock valued at $21,404,000 after acquiring an additional 65,094 shares in the last quarter. Jane Street Group LLC boosted its position in GALAPAGOS NV/S by 214.1% during the 3rd quarter. Jane Street Group LLC now owns 185,269 shares of the biotechnology company’s stock valued at $20,830,000 after acquiring an additional 126,277 shares in the last quarter. Finally, Laurion Capital Management LP bought a new stake in GALAPAGOS NV/S during the 3rd quarter valued at approximately $19,841,000. 15.81% of the stock is currently owned by institutional investors.

Shares of GLPG opened at $98.78 on Monday. GALAPAGOS NV/S has a 52 week low of $85.00 and a 52 week high of $122.28. The company has a market capitalization of $5.09 billion, a PE ratio of -37.42 and a beta of 1.65.

Several research firms have weighed in on GLPG. Leerink Swann began coverage on GALAPAGOS NV/S in a research report on Friday, February 22nd. They set an “outperform” rating and a $140.00 price objective on the stock. ValuEngine cut GALAPAGOS NV/S from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, January 2nd. BidaskClub cut GALAPAGOS NV/S from a “buy” rating to a “hold” rating in a research report on Friday, January 25th. Svb Leerink began coverage on GALAPAGOS NV/S in a research report on Friday, February 22nd. They set an “outperform” rating on the stock. Finally, Zacks Investment Research raised GALAPAGOS NV/S from a “hold” rating to a “buy” rating and set a $115.00 price objective on the stock in a research report on Tuesday, December 11th. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $123.64.

WARNING: This piece of content was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/4229679/galapagos-nv-s-glpg-position-increased-by-comerica-bank.html.

About GALAPAGOS NV/S

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Featured Article: How to calculate the intrinsic value of a stock

Want to see what other hedge funds are holding GLPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GALAPAGOS NV/S (NASDAQ:GLPG).

Institutional Ownership by Quarter for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

United Airlines trims growth Strategy for 2019
United Airlines trims growth Strategy for 2019
Surgery Partners  Reaches New 12-Month Low at $9.14
Surgery Partners Reaches New 12-Month Low at $9.14
B&G Foods, Inc.  Receives Average Rating of “Hold” from Brokerages
B&G Foods, Inc. Receives Average Rating of “Hold” from Brokerages
Recent Analysts’ Ratings Changes for ADMA Biologics
Recent Analysts’ Ratings Changes for ADMA Biologics
Wink  Trading 27.1% Higher  This Week
Wink Trading 27.1% Higher This Week
Rolls-Royce Holding PLC  Receives Average Recommendation of “Hold” from Brokerages
Rolls-Royce Holding PLC Receives Average Recommendation of “Hold” from Brokerages


© 2006-2019 Ticker Report